BioNTech Historical Income Statement
| BNTX Stock | USD 88.82 0.87 0.99% |
Historical analysis of BioNTech income statement accounts such as Net Interest Income of 367.2 M, Interest Income of 375.5 M or Discontinued Operations of 0.0 can show how well BioNTech SE performed in making a profits. Evaluating BioNTech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of BioNTech's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining BioNTech SE latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioNTech SE is a good buy for the upcoming year.
BioNTech |
About BioNTech Income Statement Analysis
BioNTech SE Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to BioNTech shareholders. The income statement also shows BioNTech investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
BioNTech Income Statement Chart
BioNTech SE Income Statement is one of the three primary financial statements used for reporting BioNTech's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of BioNTech SE revenue and expense. BioNTech Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, BioNTech's Net Income Applicable To Common Shares is fairly stable compared to the past year. Add Fundamental
Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Total Revenue
Total revenue comprises all receipts BioNTech SE generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of BioNTech SE. It is also known as BioNTech overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from BioNTech's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. At this time, BioNTech's Net Income Applicable To Common Shares is fairly stable compared to the past year.
BioNTech income statement Correlations
Click cells to compare fundamentals
BioNTech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioNTech income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Tax Provision | (268K) | (161M) | 4.8B | 3.5B | 255.8M | 243.0M | |
| Net Interest Income | (263K) | (3.5M) | (25.8M) | 311.4M | 349.7M | 367.2M | |
| Interest Income | 1.8M | 1.6M | 1.5M | 330.3M | 357.6M | 375.5M | |
| Depreciation And Amortization | 35.4M | 40.3M | (313.1M) | 453.6M | 183.4M | 192.6M | |
| Interest Expense | 1.7M | 64.9M | 5.4M | 18.9M | 7.7M | 7.4M | |
| Selling General Administrative | 40.7M | 94.0M | 278.5M | 484.7M | 495M | 519.8M | |
| Selling And Marketing Expenses | 2.7M | 14.5M | 50.4M | 59.5M | 62.7M | 65.8M | |
| Total Revenue | 108.6M | 482.3M | 19.0B | 17.3B | 3.8B | 6.4B | |
| Gross Profit | (135.2M) | (222.0M) | 15.1B | 12.8B | 3.2B | 4.8B | |
| Other Operating Expenses | 290.1M | 564.7M | 4.1B | 4.7B | 2.9B | 2.0B | |
| Operating Income | (181.5M) | (82.4M) | 15.3B | 12.6B | 690.4M | 655.9M | |
| Net Income From Continuing Ops | (179.2M) | 15.2M | 10.3B | 9.4B | 930.3M | 883.8M | |
| Ebit | (181.5M) | (82.4M) | 15.3B | 12.6B | 972M | 923.4M | |
| Research Development | 226.5M | 645.0M | 102.7M | 116M | 1.8B | 1.9B | |
| Ebitda | (146.2M) | (42.1M) | 15.0B | 13.1B | 1.2B | 1.1B | |
| Cost Of Revenue | 243.8M | 704.4M | 3.9B | 4.5B | 599.8M | 569.8M | |
| Total Operating Expenses | 46.3M | (139.6M) | 200.1M | 135.9M | 2.3B | 2.4B | |
| Reconciled Depreciation | 33.9M | 38.7M | 75.2M | 123.3M | 183.4M | 192.6M | |
| Income Before Tax | (179.4M) | (145.8M) | 15.0B | 13.0B | 1.2B | 1.1B | |
| Total Other Income Expense Net | 2.1M | (63.4M) | (237.4M) | 311.4M | (67.8M) | (64.4M) | |
| Net Income Applicable To Common Shares | (48.0M) | (179.1M) | 15.2M | 10.3B | 11.8B | 12.4B | |
| Net Income | (179.2M) | 15.2M | 10.3B | 9.4B | 930.3M | 883.8M | |
| Income Tax Expense | (268K) | (161M) | 4.8B | 3.5B | 255.8M | 243.0M |
Pair Trading with BioNTech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will appreciate offsetting losses from the drop in the long position's value.Moving together with BioNTech Stock
| 0.76 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
| 0.67 | ELAN | Elanco Animal Health Financial Report 14th of May 2024 | PairCorr |
Moving against BioNTech Stock
| 0.69 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.64 | HCM | HUTCHMED DRC | PairCorr |
| 0.57 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.51 | FLGC | Flora Growth Corp Buyout Trend | PairCorr |
The ability to find closely correlated positions to BioNTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNTech SE to buy it.
The correlation of BioNTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNTech SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioNTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share 4.1 | Revenue Per Share 15.873 | Quarterly Revenue Growth (0.65) | Return On Assets 0.0262 |
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.